GlassScriptPhysician profile
Ahmed E Badr
NPI 1508818253
$2,501.06
in general payments reported to CMS, 2019-2025
13 companies · $674 in 2025
The $674 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $324 · 2020: $112 · 2021: $250 · 2022: $134 · 2023: $17.28 · 2024: $989 · 2025: $674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,445 · Travel and Lodging: $236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,445.12 |
| Travel and Lodging | $235.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb Sa | $501.61 | 2024 | |
| Glaxosmithkline, LLC. | $403.68 | 2019-2025 | Nucala |
| Bayer Healthcare Pharmaceuticals INC. | $292.37 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $252.20 | 2024-2025 | Airsupra, Breztri |
| Boston Scientific Corporation | $218.52 | 2020-2022 | |
| Lilly USA, LLC | $216.16 | 2024-2025 | Zepbound, Mounjaro |
| Grifols USA, LLC | $161.93 | 2025 | Prolastin-C Liquid |
| Viatris Specialty LLC | $125.00 | 2025 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.82 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $100.82 | 2019 | |
| Merck Sharp & Dohme LLC | $72.48 | 2019-2020 | |
| Allergan, INC. | $21.19 | 2019 | |
| Baxter Healthcare | $17.28 | 2023 | Hillrom - Vest System Model 105 Home Care |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmed Badr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.